中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
2期
179-181
,共3页
张利峰%孙密欣%张俊芳%王桂东%刘素梅
張利峰%孫密訢%張俊芳%王桂東%劉素梅
장리봉%손밀흔%장준방%왕계동%류소매
替罗非班%可溶性CD40配体%基质金属蛋白酶-9%酶联免疫吸附测定%急性冠状动脉综合征
替囉非班%可溶性CD40配體%基質金屬蛋白酶-9%酶聯免疫吸附測定%急性冠狀動脈綜閤徵
체라비반%가용성CD40배체%기질금속단백매-9%매련면역흡부측정%급성관상동맥종합정
Tirofiban%sCD40L%matrix Metalloproteinase-9%ELISA%Acute coronary synarome
目的 观察替罗非班对急性冠状动脉综合征(ACS)患者经皮冠状动脉成形术(PCI)术后基质金属蛋白酶-9(MMP-9)与可溶性CD40配体(sCD40L)的影响.探讨该药抗炎及稳定斑块的作用机制.方法 选择ACS患者86例,随机分为对照组和不同时间段替罗非班组,PCI术后6、12、24、36 h分别抽取患者血液,应用夹心酶联免疫吸附测定法(ELISA)检测患者MMP9和sCD40L浓度的变化.结果 应用替罗非班后6、12、24、36 h MMP-9的表达从(228.25±0.02)μg/L降至(53.56±0.02)μg/L；sCD40L的表达从(321.12±0.02)ng/L降至(123.32±0.02)ng/L,与对照组[MMP-9:(319.66±0.02)μg/L;sCD40L:(392.33±0.02)μg/L]比较,差异均有统计学意义(P均＜0.05).结论 替罗非班能抑制sCD40L以及MMP-9的表达,替罗非班对MMP-9的抑制作用与CD40/CD40L信号通路相关,此作用可能是其减轻动脉粥样斑块炎症,防止斑块破裂的机制之一.
目的 觀察替囉非班對急性冠狀動脈綜閤徵(ACS)患者經皮冠狀動脈成形術(PCI)術後基質金屬蛋白酶-9(MMP-9)與可溶性CD40配體(sCD40L)的影響.探討該藥抗炎及穩定斑塊的作用機製.方法 選擇ACS患者86例,隨機分為對照組和不同時間段替囉非班組,PCI術後6、12、24、36 h分彆抽取患者血液,應用夾心酶聯免疫吸附測定法(ELISA)檢測患者MMP9和sCD40L濃度的變化.結果 應用替囉非班後6、12、24、36 h MMP-9的錶達從(228.25±0.02)μg/L降至(53.56±0.02)μg/L；sCD40L的錶達從(321.12±0.02)ng/L降至(123.32±0.02)ng/L,與對照組[MMP-9:(319.66±0.02)μg/L;sCD40L:(392.33±0.02)μg/L]比較,差異均有統計學意義(P均＜0.05).結論 替囉非班能抑製sCD40L以及MMP-9的錶達,替囉非班對MMP-9的抑製作用與CD40/CD40L信號通路相關,此作用可能是其減輕動脈粥樣斑塊炎癥,防止斑塊破裂的機製之一.
목적 관찰체라비반대급성관상동맥종합정(ACS)환자경피관상동맥성형술(PCI)술후기질금속단백매-9(MMP-9)여가용성CD40배체(sCD40L)적영향.탐토해약항염급은정반괴적작용궤제.방법 선택ACS환자86례,수궤분위대조조화불동시간단체라비반조,PCI술후6、12、24、36 h분별추취환자혈액,응용협심매련면역흡부측정법(ELISA)검측환자MMP9화sCD40L농도적변화.결과 응용체라비반후6、12、24、36 h MMP-9적표체종(228.25±0.02)μg/L강지(53.56±0.02)μg/L；sCD40L적표체종(321.12±0.02)ng/L강지(123.32±0.02)ng/L,여대조조[MMP-9:(319.66±0.02)μg/L;sCD40L:(392.33±0.02)μg/L]비교,차이균유통계학의의(P균＜0.05).결론 체라비반능억제sCD40L이급MMP-9적표체,체라비반대MMP-9적억제작용여CD40/CD40L신호통로상관,차작용가능시기감경동맥죽양반괴염증,방지반괴파렬적궤제지일.
Objective To investigate the effects of Tirofiban on the expression of matrix metalloproteinase(MMP-9)and sCD40L in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI)and to explore the potential mechanism of anti-artherosclerosis and stabilize plaque by Tirofiban.Methods Eighty-six patients with ACS were enrolled and were randomly divided into the control group and the Tirofiban group with different time periods after PCI.The expression of MMP-9 and sCD40L were tested by ELISA at 6 h,12 h,24 h,36 h after PCI.Results After application of Tirofiban 6 h,12 h,24 h,36 h,the expression of MMP-9 decreased from(228.25 ±0.015)ug/L to(53.56 ±0.02)μg/L and the expression of sCD40L decreased from(321.12 ±0.02)ng/L to(123.32 ±0.02)ng/L,compared with the control group,the difference was significant(P ＜ 0.05).Conclusions Tirofiban can inhibite the expression of sCD40L and MMP-9,the inhibition of the expression of MMP-9 may be related to the CD40/CD40L pathway.This effect may be one of the mechanism of reducing atherosclerotic plaque inflammation and preventing plaque rupture by Tirofiban.
